TEST:

oncoReveal™ Essential LBx

In a separate FFPE dataset using the OncoReveal® Essential Lbx panel, we show that the marginal log likelihood cleanly separates, degraded from high-quality samples, even when conventional sequencing QC metrics do not. BayesCNV provides accurate and interpretable gene-level CNV estimates and uncertainty quantification, along with an evidence-based quality control metric that improves robustness in targeted cfDNA workflows.

"Pillar Biosciences, Inc. has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling panels for detection of genetic cancer variants, with an initial focus on European markets and the UK...The partnership aims to rapidly identify tumors with clinically actionable genomic alterations via liquid biopsy profiling and intends to support faster diagnostic testing by increasing the local availability of plasma-based tumor profiling at leading clinical laboratories....The work will initially leverage Pillar Biosciences oncoReveal Core LBx, Essential LBx, and Fusion LBx research-use-only (RUO) liquid biopsy kitted NGS panels."